secwatch.observer — SEC 8-K summary
======================================

Issuer:     TransMedics Group, Inc. (TMDX)
CIK:        0001756262
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-066916
Event type: earnings
Sentiment:  positive
Materiality: 0.78
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransMedics Q1 revenue $143.5M (+48% YoY), net income $25.7M; raises FY2025 guidance to $565-585M
--------------------------------------------------------------------------------

- Q1 revenue $143.5M (+48% YoY from $96.9M); net income $25.7M ($0.70 diluted EPS), up from $12.2M in Q1 2024.
- Gross margin 61% vs 62% a year ago; operating expenses $60.8M (incl. $8.7M stock comp) vs $47.5M.
- FY2025 revenue guidance raised to $565-585M (from $530-552M), representing ~30% YoY growth at midpoint.
- Cash balance $310.1M as of March 31, 2025; owned 21 aircraft for organ logistics.
- Announced design center and manufacturing facility in Mirandola, Italy; 10 abstracts at ISHLT meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1756262/000095017025066916/0000950170-25-066916-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1756262/000095017025066916/tmdx-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-066916

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer